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The European Spine Journal acknowledges the increasing
attention for economic evaluations and would like to
stimulate researchers to submit original papers of economic
evaluations of orthopedic devices/instruments and surgical
interventions for spine problems, but also pharmaceutical
and conservative interventions for back and neck pain.
Because back and neck pain are among the most prevalent
health problems and are associated with huge costs of
health care utilization and productivity losses, economic
evaluations in this field are direly needed to facilitate well-
informed clinical and policy decisions.
Health care systems in western countries are becoming
more expensive every year. OECD health data from 2010
show that most western countries spend about 8–16% of
their gross national product on health care. Although this
percentage will even grow in the near future, we cannot
afford to reimburse all available health care interventions.
Consequently, policy makers have to make decisions about
inclusion (or exclusion) of interventions in public health
insurance systems.
To be able to make well-informed decisions, it is of
utmost importance that policy makers have valid and
reliable information available about safety, effectiveness
and cost effectiveness of interventions. Health technology
assessment (HTA) is a reasonably new field of scientific
research that involves evaluation of health interventions
(technologies). These can be preventive, diagnostic or
therapeutic interventions and either new or existing inter-
ventions. Some overlap exists between HTA and public
health research and (clinical) epidemiology, as these dis-
ciplines also evaluate effectiveness of interventions.
However, besides effectiveness HTA also looks at other
aspects, such as costs, side effects, organizational, legal or
ethical aspects.
Ideally, interventions should be evaluated before they
are widely used, because it is really difficult to withdraw
interventions from the health care system. In many coun-
tries, regulations for new pharmaceutical interventions are
strict, but none exist for medical devices or non-pharma-
ceutical interventions. New drugs are only reimbursed in
public health insurance systems if they are proven to be
safe, effective, and cost effective compared to existing
drugs for the same disease or disorder. However, new
physical therapies, new exercise therapies or new surgical
techniques can be introduced without first having been
scrutinized in scientific research. I would argue that it is
time to also start evaluating effectiveness and cost effec-
tiveness of new surgical and non-pharmacological inter-
ventions before they are widely used.
Economic evaluations are systematic comparisons of
two or more health technologies, services or programs in
terms of both costs and consequences. This simultaneous
comparison of the costs and consequences provides insight
into which intervention is worth doing over another or
whether the additional costs of an intervention are worth
the effects. Economic evaluations do not necessarily
answer the question what the cheapest intervention is. If an
intervention is more effective than another intervention but
associated with higher costs, the intervention may still be
cost effective.
During the last decade, the number of economic evalu-
ations that have been conducted and published has
increased. Similar to other types of research, it is of utmost
importance that economic evaluations are conducted
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according to the state-of-the-art and that their results are
valid and reliable. Knowledge of the methodology of
economic evaluation is necessary.
Four types of economic evaluations exist, i.e., cost
effectiveness, cost utility, cost benefit, and cost minimi-
zation analysis. The principles of these types of economic
evaluations are similar; the difference is the way in which
the outcomes are expressed. Cost-effectiveness and cost-
utility analyses are the most commonly used. In cost-
effectiveness analysis, outcomes are disease specific, and
in cost-utility analysis outcomes are patients’ preferences,
which are expressed as quality-adjusted life-years (QA-
LYs) or disability-adjusted life-years. The methods of
economic evaluations include choosing the alternatives;
identifying the perspective; identifying, measuring and
valuing costs; identifying, measuring and valuing effects;
and analyzing the data.
Usually economic evaluations are performed from a
societal perspective taking all costs and consequences into
account. However, sometimes another perspective is chosen,
e.g., that of the national health care system (NHS in the UK),
or that of the company or employer. The latter is relevant for
economic evaluations of interventions in an occupational
setting. The perspective chosen defines which costs and
outcomes are considered in the economic evaluation and
whether results can be generalized to other settings.
Economic evaluations always compare two or more
alternatives. The best alternative is ‘usual care’ or the best
or most widely used alternative, since these are the most
informative comparisons to policy makers. If a new inter-
vention is cost effective compared with usual care,
implementation of this intervention is useful.
Costs are usually classified as direct and indirect costs,
within and outside the healthcare sector. Direct costs within
the healthcare sector include all costs of healthcare utili-
zation. These costs include, e.g., costs of general practi-
tioner care, medication, physical therapy, surgery and
hospitalization.
Direct costs outside the health care sector include costs
of complementary and alternative care and patients’ out-of-
pocket costs. Indirect costs outside the healthcare sector
include costs of productivity loss, i.e., costs of absenteeism
(loss of productivity while off work) and presenteeism (loss
of productivity while at work). Especially in the field of
spine research, these costs are often much higher than the
direct costs.
Costs are often not measured directly, but through health
care utilization or resource use. When all relevant resource
data have been collected, the next step is valuing the costs.
Costs are resource use multiplied with valid unit prices.
Analyzing and interpreting data from economic evalu-
ations are challenging, because cost data are typically
skewed. Often there are only a few subjects with high
health care utilization or long periods of work absenteeism,
and therefore a relatively small number of patients with
high costs. Non-parametric analysis is used to deal with
skewed data and bootstrapping is a method commonly used
in economic evaluations. The outcome of economic eval-
uations is an incremental cost-effectiveness ratio (ICER),
which is estimated for each outcome. The ICER is the ratio
of the difference in costs of the intervention and its alter-
native divided by the difference in effects and indicates the
additional investments needed to gain one extra unit of
effect. Uncertainty of the ICER is expressed on a so-called
cost-effectiveness plane, which shows the bootstrap esti-
mates. The x-axis represents the difference in effects and
the y-axis represents the difference in costs. Cost-effec-
tiveness acceptability curves help interpreting results of
economic evaluations. They show the probability that an
intervention is cost effective for a wide range of threshold
ratios that policymakers would be willing to pay.
As stated before, healthcare expenditures are rising,
budgets are getting tighter, and choices have to be made
about providing or reimbursing healthcare interventions.
These choices should be made based on available evidence
regarding safety, effectiveness and cost effectiveness.
Information on safety should come from observational
studies, information on effectiveness from randomized
controlled trials and information on cost effectiveness from
economic evaluations. These studies should have adequate
sample sizes and be well designed so that their results are
precise, valid and reliable and lead to well-informed clin-
ical and policy decisions.
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